Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 657 - 664 of 11617 results
EnforceMintz — Practical Lessons Learned from FCA Litigation in 2023
February 8, 2024| Blog| Viewpoint
EnforceMintz — Government Scrutiny of Medicare Advantage Organizations Expected to Continue in 2024
February 8, 2024| Blog| Viewpoint
EnforceMintz — 2023 Brings Uptick in Cybersecurity Enforcement, Insight Into Potential Risks
February 8, 2024| Blog| Viewpoint
EnforceMintz — Despite Few Enforcement Actions in 2023, PE Investment in Health Care Remains a Hot Topic
February 8, 2024| Blog| Viewpoint
EnforceMintz — Tele-Fraud Enforcement in 2023 Remained Focused on Same Schemes as Years Past
February 8, 2024| Blog| Viewpoint
EnforceMintz — COVID-19 Fraud Enforcement Unlikely to Slow Down in 2024
February 8, 2024| Blog| Viewpoint
Senators Propose Clarification of Antitrust Law to Expressly Cover Algorithmic Collusion — AI: The Washington Report
February 8, 2024| Article| Viewpoint
ESG Political Partisanship: Guidance for In House Counsel
February 7, 2024| Podcast| Viewpoint
News & Press Releases
Mintz Announces New Members
December 20, 2024
Mintz announces the election of eight attorneys to Members, effective January 1, 2025. The newly promoted Members join the ranks of the firm’s growing membership, including six new lateral Members who joined the firm in 2024.
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Dealmaking Dormant No More
December 17, 2024
International Chair of Life Sciences Cheryl Reicin recently participated in a Q&A with Pharmaceutical Executive in which she discusses the ongoing effects of the pandemic on dealmaking trends in the pharmaceutical industry. Cheryl specifically mentions how M&A activity began to rise again in 2024 after slowing in 2023, and that she expects acquisitions to continue picking up in 2025.
Events
Podcasts
The ‘Third Inning’ of the Energy Transition
December 6, 2024| Podcast|
Mintz on Air - Predictions and Practical Policies
November 25, 2024| Podcast|